title: A Comparison of Seven Cox Regression-Based Models to Account for Heterogeneity Across Multiple HIV Treatment Cohorts in Latin America and the Caribbean.
abstract: Many studies of HIV/AIDS aggregate data from multiple cohorts to improve power and generalizability. There are several analysis approaches to account for cross-cohort heterogeneity; we assessed how different approaches can impact results from an HIV/AIDS study investigating predictors of mortality. Using data from 13,658 HIV-infected patients starting antiretroviral therapy from seven Latin American and Caribbean cohorts, we illustrate the assumptions of seven readily implementable approaches to account for across cohort heterogeneity with Cox proportional hazards models, and we compare hazard ratio estimates across approaches. As a sensitivity analysis, we modify cohort membership to generate specific heterogeneity conditions. Hazard ratio estimates varied slightly between the seven analysis approaches, but differences were not clinically meaningful. Adjusted hazard ratio estimates for the association between AIDS at treatment initiation and death varied from 2.00 to 2.20 across approaches that accounted for heterogeneity; the adjusted hazard ratio was estimated as 1.73 in analyses that ignored across cohort heterogeneity. In sensitivity analyses with more extreme heterogeneity, we noted a slightly greater distinction between approaches. Despite substantial heterogeneity between cohorts, the impact of the specific approach to account for heterogeneity was minimal in our case study. Our results suggest that it is important to account for across cohort heterogeneity in analyses, but that the specific technique for addressing heterogeneity may be less important. Because of their flexibility in accounting for cohort heterogeneity, we prefer stratification or meta-analysis methods, but we encourage investigators to consider their specific study conditions and objectives.
authors: 1 Department of Biostatistics, Vanderbilt University School of Medicine , Nashville, Tennessee.
authors: Mark J
authors: MJ
authors: Giganti
authors: Paula M
authors: PM
authors: Luz
authors: Yanink
authors: Y
authors: Caro-Vega
authors: Carina
authors: C
authors: Cesar
authors: Denis
authors: D
authors: Padgett
authors: Serena
authors: S
authors: Koenig
authors: Juan
authors: J
authors: Echevarria
authors: Catherine C
authors: CC
authors: McGowan
authors: Bryan E
authors: BE
authors: Shepherd
mesh_terms: D000293:Adolescent; D000328:Adult; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D056808:Biostatistics / Q000379:methods*; D017691:Caribbean Region / Q000453:epidemiology; D015331:Cohort Studies; D004812:Epidemiologic Methods; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000401:mortality*; D006801:Humans; D007843:Latin America / Q000453:epidemiology; D008297:Male; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D044966:Anti-Retroviral Agents
references: Biometrics. 1978 Mar;34(1):57-67
references: 630037
references: Int J Epidemiol. 2012 Dec;41(6):1807-20
references: 23148105
references: Biometrics. 1992 Sep;48(3):795-806
references: 1420842
references: Stat Med. 2005 May 15;24(9):1307-19
references: 15685717
references: Am J Epidemiol. 2006 Jun 1;163(11):1053-64
references: 16624970
references: Int J Epidemiol. 2007 Apr;36(2):294-301
references: 17213214
references: Int J Epidemiol. 2007 Oct;36(5):969-76
references: 17846055
references: PLoS Med. 2007 Oct 16;4(10):e298
references: 17941716
references: Clin Infect Dis. 2014 May;58(9):1312-21
references: 24457342
references: Int J Epidemiol. 2014 Jun;43(3):691-702
references: 23599235
references: PLoS Med. 2014 Sep;11(9):e1001718
references: 25203931
references: Clin Infect Dis. 2011 Dec;53(11):1130-9
references: 21998280
references: Contemp Clin Trials. 2008 Mar;29(2):220-30
references: 17884735
references: JAMA. 2008 Aug 6;300(5):506-7
references: 18677022
references: J Clin Epidemiol. 2009 Jul;62(7):729-37
references: 19108987
references: PLoS One. 2009;4(6):e5790
references: 19495419
references: J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):615-23
references: 19430306
references: PLoS Med. 2011;8(1):e1000390
references: 21267057
references: PLoS Med. 2011;8(2):e1000416
references: 21358808
references: J Acquir Immune Defic Syndr. 2011 Nov 1;58(3):269-76
references: 21876447
references: Stat Med. 2002 Nov 15;21(21):3219-33
references: 12375300
references: AIDS. 2002 Dec;16 Suppl 3:S3-12
references: 12685919
references: Stat Med. 2004 Feb 15;23(3):369-88
references: 14748034
references: PLoS One. 2013;8(5):e64459
references: 23691224
references: J Acquir Immune Defic Syndr. 2014 May 1;66(1):74-9
references: 24413039
references: Lancet Infect Dis. 2012 Jan;12(1):19-26
references: 21975269
references: Int J Epidemiol. 2012 Oct;41(5):1256-64
references: 21593078
references: Control Clin Trials. 1986 Sep;7(3):177-88
references: 3802833